Compare Ascendis Pharma A/S (ASND) vs BlackRock TCP Capital Corp (TCPC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ascendis Pharma A/S vs BlackRock TCP Capital Corp — how do they compare? Ascendis Pharma A/S trades at $270.45 (market cap $17.74B), while BlackRock TCP Capital Corp trades at $3.24 (market cap $273.10M). The key difference: Ascendis Pharma A/S is far larger — about 65× BlackRock TCP Capital Corp's market cap, and BlackRock TCP Capital Corp pays a 25.81% dividend while Ascendis Pharma A/S pays none. Which is the better fit depends on your goals.
| ASND | TCPC | |
|---|---|---|
Market Cap | $17.74B | $273.10M |
Sector | Health | Financials |
52-Week High | $277.18 | $7.90 |
52-Week Low | $163.32 | $3.14 |
Enterprise Value | $18.11B | — |
Dividend Yield | — | 25.81% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.
The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.
TCPC trades at $3.26, up 3.16% today, but faces a bearish technical outlook with negative revenue and net income trends. The company reported a net loss of $88.93M for 2025 with revenue of -$77.27M, though it maintains a dividend yield above 10%. Recent news highlights potential dividend sustainability concerns and an ongoing legal investigation into corporate governance.
The outlook remains challenging with declining fundamentals and bearish technical signals. Investment opportunities exist for income-focused investors due to high dividend yield, but risks include persistent losses, legal scrutiny, and negative analyst sentiment with only 30.77% buy ratings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About BlackRock TCP Capital Corp
BlackRock TCP Capital Corp is a finance company specializing in middle-market lending. It aims for high returns through income and capital appreciation while prioritizing principal protection. The company invests in debt securities and earns revenue from interest payments, fees, and some equity appreciation.
Read more on TCPC →
